The Australian market has experienced a mix of reactions recently, with the IT sector making gains despite broader concerns about inflation and materials sector performance. In such an environment, growth companies with substantial insider ownership can be appealing as they often signal confidence from those closest to the business.

Top 10 Growth Companies With High Insider Ownership In Australia

Name Insider Ownership Earnings Growth Wisr (ASX:WZR) 10.4% 96.4% Titomic (ASX:TTT) 11.2% 74.9% Polymetals Resources (ASX:POL) 37.7% 108% Pointerra (ASX:3DP) 19.8% 110.3% Newfield Resources (ASX:NWF) 31.5% 72.1% IRIS Metals (ASX:IR1) 23.5% 144.4% IperionX (ASX:IPX) 16.9% 94.9% Elsight (ASX:ELS) 17.3% 77% Echo IQ (ASX:EIQ) 19.1% 51.4% Adveritas (ASX:AV1) 18.4% 96.8%

Click here to see the full list of 109 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

Mesoblast

Simply Wall St Growth Rating: ★★★★★★

Overview: Mesoblast Limited, along with its subsidiaries, focuses on developing regenerative medicine products across Australia, the United States, Singapore, and Switzerland with a market cap of A$3.45 billion.

Operations: The company's revenue segment primarily consists of the development of its cell technology platform for commercialization, generating $17.20 million.

Insider Ownership: 32.8%

Mesoblast is poised for substantial growth, with revenue forecasted to increase by 44.3% annually, outpacing the Australian market. The company expects profitability within three years and has seen significant insider buying recently. Mesoblast's recent collaboration with NIH for a pivotal trial of Ryoncil® in adults and its FDA discussions on opioid reduction highlight potential expansion avenues. Additionally, new CFO James M. O'Brien brings extensive financial expertise to support strategic growth initiatives.

Dive into the specifics of Mesoblast here with our thorough growth forecast report. In light of our recent valuation report, it seems possible that Mesoblast is trading behind its estimated value.ASX:MSB Ownership Breakdown as at Nov 2025

PolyNovo

Simply Wall St Growth Rating: ★★★★★☆

Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices across several countries including Australia, New Zealand, the United States, and others, with a market cap of A$829.01 million.

Operations: The company's revenue is primarily derived from the development, manufacturing, and commercialization of the NovoSorb technology, amounting to A$128.70 million.

Insider Ownership: 10.5%

PolyNovo is experiencing robust growth, with earnings projected to expand by 27.37% annually, surpassing the Australian market's average. Despite being dropped from the S&P/ASX 200 Index, insider confidence remains strong with substantial recent insider buying and no significant selling. The company's shares are trading at a notable discount of 25.7% below estimated fair value, while its revenue growth forecast of 14.8% per year exceeds the broader market rate of 6%.

Story Continues

Click to explore a detailed breakdown of our findings in PolyNovo's earnings growth report. Our valuation report unveils the possibility PolyNovo's shares may be trading at a premium.ASX:PNV Ownership Breakdown as at Nov 2025

PYC Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: PYC Therapeutics Limited is an Australian drug-development company focused on discovering and developing novel RNA therapeutics for genetic diseases, with a market cap of approximately A$895.30 million.

Operations: The company's revenue segment is primarily derived from its activities in the discovery and development of novel RNA therapeutics, amounting to A$23.49 million.

Insider Ownership: 38.3%

PYC Therapeutics is seeing insider confidence, evidenced by substantial recent insider buying and no significant selling. Despite trading significantly below its estimated fair value, the company faces challenges with a net loss of A$50.3 million for the year ended June 2025 and auditor concerns about its going concern status. However, revenue is forecast to grow at 10.3% annually, outpacing the broader Australian market's growth rate of 6%, with profitability expected within three years.

Click here and access our complete growth analysis report to understand the dynamics of PYC Therapeutics. Our expertly prepared valuation report PYC Therapeutics implies its share price may be too high.ASX:PYC Ownership Breakdown as at Nov 2025

Where To Now?

Gain an insight into the universe of 109 Fast Growing ASX Companies With High Insider Ownership by clicking here. Contemplating Other Strategies? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ASX:MSB ASX:PNV and ASX:PYC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments